(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 282.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.03%.
Ensysce Biosciences's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ENSC's revenue for 2025 to be $9,933,240, with the lowest ENSC revenue forecast at $0, and the highest ENSC revenue forecast at $20,450,788. On average, 4 Wall Street analysts forecast ENSC's revenue for 2026 to be $0, with the lowest ENSC revenue forecast at $0, and the highest ENSC revenue forecast at $0.
In 2027, ENSC is forecast to generate $315,391,876 in revenue, with the lowest revenue forecast at $303,022,248 and the highest revenue forecast at $324,669,983.